Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader-Willi Syndrome: A Randomized Crossover Trial
Por:
Amat-Bou M, Garcia-Ribera S, Climent E, Piquer-Garcia I, Corripio R, Sánchez-Infantes D, Villalta L, Elias-Abadias M, Jimenez-Chillaron JC, Chenoll E, Ramón D, Ibañez-Toda L, Ramon-Krauel M and Lerin C
Publicada:
1 oct 2020
Ahead of Print:
13 oct 2020
Resumen:
Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by a wide range of clinical manifestations, including obesity, hyperphagia, and behavioral problems. Bifidobacterium animalis subsp. lactis strain BPL1 has been shown to improve central adiposity in adults with simple obesity. To evaluate BPL1 ' s effects in children with PWS, we performed a randomized crossover trial among 39 patients (mean age 10.4 years). Participants were randomized to placebo-BPL1 (n = 19) or BPL1-placebo (n = 20) sequences and underwent a 12-week period with placebo/BPL1 treatments, a 12-week washout period, and a 12-week period with the crossover treatment. Thirty-five subjects completed the study. The main outcome was changes in adiposity, measured by dual-energy X-ray absorptiometry. Secondary outcomes included lipid and glucose metabolism, hyperphagia, and mental health symptoms. Generalized linear modeling was applied to assess differences between treatments. While BPL1 did not modify total fat mass compared to placebo, BPL1 decreased abdominal adiposity in a subgroup of patients older than 4.5 years (n = 28). BPL1 improved fasting insulin concentration and insulin sensitivity. Furthermore, we observed modest improvements in some mental health symptoms. A follow-up trial with a longer treatment period is warranted to determine whether BPL1 supplementation can provide a long-term therapeutic approach for children with PWS (ClinicalTrials.gov NCT03548480).
Filiaciones:
Amat-Bou M:
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain
Endocrinology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain
Garcia-Ribera S:
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain
Endocrinology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain
Climent E:
Archer Daniels Midland Co-Biopolis, 46980 Valencia, Spain
Piquer-Garcia I:
Department of Endocrinology and Nutrition, Germans Trias i Pujol Research Institute, 08916 Barcelona, Spain
Corripio R:
Service of Pediatric Endocrinology, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, 08208 Sabadell, Spain
Sánchez-Infantes D:
Department of Endocrinology and Nutrition, Germans Trias i Pujol Research Institute, 08916 Barcelona, Spain
CIBEROBN, Instituto de Salud Carlos III, 28029 Madrid, Spain
Villalta L:
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain
Child and Adolescent Psychiatry and Psychology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain
Elias-Abadias M:
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain
Child and Adolescent Psychiatry and Psychology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain
Jimenez-Chillaron JC:
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain
Endocrinology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain
Chenoll E:
Archer Daniels Midland Co-Biopolis, 46980 Valencia, Spain
Ramón D:
Archer Daniels Midland Co-Biopolis, 46980 Valencia, Spain
Ibañez-Toda L:
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain
Endocrinology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain
CIBERDEM, Instituto de Salud Carlos III, 28029 Madrid, Spain
Ramon-Krauel M:
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain
Endocrinology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain
Lerin C:
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain
Endocrinology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain
Green Submitted, gold
|